Dr. Ragini R. Kudchadkar, MD
Claim this profileWinship Cancer Institute, Emory University
Studies Skin Cancer
Studies Squamous Cell Carcinoma
4 reported clinical trials
5 drugs studied
Area of expertise
1Skin Cancer
Stage III
Stage IV
2Squamous Cell Carcinoma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Ragini R. Kudchadkar, MD is currently running
Cemiplimab with Surgery
for High-Risk Skin Cancer
This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cemiplimab before surgery may improve risk of the cancer returning in patients with high risk cutaneous squamous cell cancer.
Recruiting1 award Phase 1
TSR-022
for Cancer
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Recruiting1 award Phase 1
More about Ragini R. Kudchadkar, MD
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ragini R. Kudchadkar, MD has experience with
- Cemiplimab
- Nivolumab
- Relatlimab
- RP1
- TSR-022
Breakdown of trials Ragini R. Kudchadkar, MD has run
Skin Cancer
Squamous Cell Carcinoma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ragini R. Kudchadkar, MD specialize in?
Ragini R. Kudchadkar, MD focuses on Skin Cancer and Squamous Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage III patients, or patients who are Stage IV.
Is Ragini R. Kudchadkar, MD currently recruiting for clinical trials?
Yes, Ragini R. Kudchadkar, MD is currently recruiting for 2 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Ragini R. Kudchadkar, MD has studied deeply?
Yes, Ragini R. Kudchadkar, MD has studied treatments such as Cemiplimab, Nivolumab, Relatlimab.
What is the best way to schedule an appointment with Ragini R. Kudchadkar, MD?
Apply for one of the trials that Ragini R. Kudchadkar, MD is conducting.
What is the office address of Ragini R. Kudchadkar, MD?
The office of Ragini R. Kudchadkar, MD is located at: Winship Cancer Institute, Emory University, Atlanta, Georgia 30322 United States. This is the address for their practice at the Winship Cancer Institute, Emory University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.